Show simple item record

dc.contributor.authorRamalingam, S. S.
dc.contributor.authorAhn, M. J.
dc.contributor.authorAkamatsu, H.
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorBorghaei, H.
dc.contributor.authorHummel, H. D.
dc.contributor.authorJohnson, M.
dc.contributor.authorReck, M.
dc.contributor.authorZhang, Y.
dc.contributor.authorJandial, D.
dc.contributor.authorCheng, S.
dc.contributor.authorPaz-Ares, L.
dc.date.accessioned2022-04-28T13:57:38Z
dc.date.available2022-04-28T13:57:38Z
dc.date.issued2022en
dc.identifier.citationRamalingam SS, Ahn MJ, Akamatsu H, Blackhall F, Borghaei H, Hummel HD, et al. Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC). Annals of Oncology. 2022;33:S103-S4.en
dc.identifier.doi10.1016/j.annonc.2022.02.186en
dc.identifier.urihttp://hdl.handle.net/10541/625145
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2022.02.186en
dc.titlePhase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)en
dc.typeMeetings and Proceedingsen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2022-06-28T09:45:06Z


Files in this item

Thumbnail
Name:
Ramalingam.pdf
Size:
101.0Kb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record